In a phase I study, the usage of IT injection of T-VEC and CD1c (BDCA-1)+ myeloid dendritic cells (myDCs) as well as CD141 (BDCA-3)+ myDCs in advanced melanoma patients who did not respond to standard therapy was evaluated (NCT03747744). This evidence concerns the gene CD1C and melanoma.